Oxford BioMedica swings to full-year loss amid lower volumes

(Alliance News) - Oxford BioMedica PLC on Tuesday reported a drop in annual revenue and swung to ...

Alliance News 25 April, 2023 | 10:34AM
Email Form Facebook Twitter LinkedIn RSS

(Alliance News) - Oxford BioMedica PLC on Tuesday reported a drop in annual revenue and swung to a loss, as a result of lower volumes and higher costs.

The Oxfordshire, England-based gene and cell therapy group posted revenue of GBP140.0 million in 2022, down from GBP142.8 million a year ago. It swung to a pretax loss of GBP46.0 million from a profit of GBP19.9 million.

The company explained that it had a strong performance by Oxford Biomedica Solutions, despite lower Covid-19 vaccine bioprocessing volumes.

In 2023, the company saw rising expenses: Research & Development costs rose to GBP60.9 million from GBP40.2 million; Bioprocessing costs jumped to GBP33.9 million from GBP7.2 million; and administration costs surged to GBP28.2 million from GBP15.1 million.

Looking ahead, in 2023, Oxford BioMedica is targeting double-digit growth in lentiviral vector and AAV manufacturing and commercial development revenues through existing client relationships and new agreements.

Chief Executive Officer Frank Mathias said: "In 2022, we have successfully grown our core business by expanding our global reach, establishing Oxford Biomedica Solutions in the US and broadening our expertise in key viral vector types, including AAV. The expansion of our development and manufacturing capabilities has enabled us to drive innovation whilst both attracting new international biopharma clients and expanding existing collaborations."

Shares in Oxford BioMedica were up 2.9% to 459.75 pence each in London on Tuesday morning.

By Sophie Rose, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

Email Form Facebook Twitter LinkedIn RSS

Securities Mentioned in Article

Security Name Price Change (%) Morningstar
Rating
Oxford BioMedica PLC 323.50 GBX -2.27 -

About Author

Alliance News

Alliance News provides Morningstar with continuously updating coverage of news affecting listed companies.

© Copyright 2024 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Modern Slavery Statement        Cookie Settings        Disclosures